BLANSETT PHARMACAL CO., INC. – Trademark Portfolio

Entity Type: 03

BLANSETT PHARMACAL CO., INC. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ANOLOR. The owner is based in Irving, TX.

c/o Exela Technologies Inc.

2701 E. GRAUWYLER RD

Irving, TX 75061

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NALEX
NALEX
Cancelled 2006
B-TUSS
B-TUSS
Cancelled 2005
RELAGARD
RELAGARD
Cancelled 2000
PROLEX
PROLEX
Cancelled 2000
NALEX
NALEX
Cancelled 1993
ANOLOR
ANOLOR
Registered 1987

Trademark Classifications

BLANSETT PHARMACAL CO., INC.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BLANSETT PHARMACAL CO., INC. have?

BLANSETT PHARMACAL CO., INC. has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 6 cancelled.

What trademark classes does BLANSETT PHARMACAL CO., INC. file in?

BLANSETT PHARMACAL CO., INC. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BLANSETT PHARMACAL CO., INC.'s most well-known trademarks?

BLANSETT PHARMACAL CO., INC.'s registered trademark portfolio includes well-known marks such as ANOLOR. These are among 1 currently registered trademark in the portfolio.

What is BLANSETT PHARMACAL CO., INC.'s trademark registration success rate?

BLANSETT PHARMACAL CO., INC. has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.